Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Biotech Goes To Work On The Coronavirus, Updated 2/12/2020

|About: Abbott Laboratories (ABT), CYDY, GILD, GLAXF, GNBT, GSK, INO, JNJ, MRNA, NNVC, NVAX, REGN, VIR
Summary

List of 14 companies working on Coronavirus.

Anthony Fauci M.D. of NIH says Regeneron and Moderna have vaccines in the works.

Coronavirus may come from nowhere to create a recession.

The consequences of the coronavirus are becoming clear. Hyundai has had to stop its assembly lines because it is lacking parts from China. This kind of thing will make it very clear to everyone the importance of China in manufacturing. Will any changes to supply chains develop from this outbreak? That remains to be seen. But what is clear is that hundreds of lives have already been taken by the disease, and it looks like coronavirus is that thing from out of nowhere that could very easily create a world recession.

Coronavirus is a class of viruses, the new novel coronavirus has been labeled 2019-nCoV, but as of Feb 12, 2020 it has a new name, Covid-19.  It appears that the new virus is similar at the 80% level to SARS, another in the coronavirus family.

Investors will be interested in those companies that are closing in on a vaccine, and the sole goal of this article is to find those companies working in the area. So, it is more of resource than an article of analysis.

It has been stated many times already that Big Pharma is not particularly interested in curing diseases but that it wants as products those kinds of things that you need to take for the rest of your life. Lipitor was ideal that way. You have to take it every day for the rest of your life to contain your LDL cholesterol. The problem with outbreaks is that they don’t last long enough that you can make any money, so they don’t invest as many of their people and assets in this area. You get a vaccine or take a course of antibiotics for a week or two, and then you’re past it. Government, so far, has found no way to interest Big Pharma in providing these medications on a sustained basis.

Though this pandemic certainly has the attention of the Chinese, who want a cure and want it now. The problem for Americans is that the Chinese are not fair ball players. They will be happy to get know and meddle in our technology, but not to honor our intellectual property, our patents. It might be an opportune time for America’s president to get the attention of the Chinese, if they want our assistance.

Anthony Fauci M.D. from the NIH provided an update here at about minute 12:

Coronavirus outbreak: U.S. confirms 12 cases, commits $100 million to help fight illness

He mentions Gilead’s remdesivir. He also mentions Moderna. And that the CDC has developed a test kit for the disease.

But it would be my guess that China will step up to fund some of this research activity, especially if isolation, their main technique as of now, fails to work. Here is an afternoon of reading.

The names I have come up with so far are these:

Gilead Pharmaceuticals (GILD)

GlaxoSmithKline (GSK)

Abbott Laboratories (ABT)

Johnson & Johnson (JNJ)

Inovio Pharmaceuticals (INO)

Cytodyn (OTCQB:CYDY)

Generex (OTCQB:GNBT)

NanoViricide (NNVC)

Moderna (MRNA)

Novavax (NVAX)

Vir Biotechnology (VIR)

Regeneron (REGN)

Gilead Pharmaceuticals

It has struck a deal with China-Japan Friendship Hospital for a trial.

Vaccine candidate: remdesivir

Articles & PR’s:

The companies working on a coronavirus vaccine

These 4 Biotech Stocks Are the Silver Lining on the Wuhan Coronavirus

GlaxoSmithKline (GSK)

GSK is offering to help with an adjuvant that aids the effectiveness of a vaccine.

Articles & PR’s:

Glaxo offers vaccine booster to fight coronavirus

These 4 Biotech Stocks Are the Silver Lining on the Wuhan Coronavirus

Abbott Laboratories (ABT)

Here is a podcast with Dr. Mary Rodgers of Abbott Laboratories. Global virus database. ABT is known for its diagnostics. Perhaps it will develop a test to identify if the patient has the novel coronavirus.

Articles & PR’s:

The Virus Hunters from Abbott Laboratories tell us what we need to know about the Wuhan coronavirus

These 4 Biotech Stocks Are the Silver Lining on the Wuhan Coronavirus

Johnson & Johnson (JNJ)

It developed a vaccine for Ebola.

Technology agent: AdVac viral vector and PER.C6 cell line technology

Articles & PR’s:

Better Coronavirus Play: Johnson & Johnson vs. Novavax | The Motley Fool

Inovio Pharmaceuticals (INO)

Technology agent: INO-4800

Articles & PR’s:

The companies working on a coronavirus vaccine

Prepare For More Dilution Of Inovio Pharmaceuticals Yet Again

A New Decade And A Fresh Start For Inovio

Investors rush into biotechs working on coronavirus vaccine

NanoViricides (NNVC)

This stock has seen quite a bit of volatility as of recently. Clinical stage biotech working in the virus area. Apparently, nothing has reached Phase I, Phase II, or Phase III testing. No products.

Technology agent: Unknown

Articles & PR’s:

NanoViricides Will Return To $3-$5 As Soon As The Coronavirus Newsflow Fades

These 4 Biotech Stocks Are the Silver Lining on the Wuhan Coronavirus

Cytodyn (OTCQB:CYDY)

Cytodyn would use the CCR5 receptor that it has used in other diseases it is working on and attempt to interrupt its activity and the disease.  It has signed a letter of intent with Longen China Group for Leronlimab for both cancer and coronavirus.

Technology agent: Leronlimab

Articles & PR’s:

Leronlimab Under Evaluation for Potential Treatment of Coronavirus

CytoDyn's Big Bang

CytoDyn Signs Letter of Intent for the Joint Development and Licensing of Leronlimab in China with Longen China Group

Generex (OTCQB:GNBT)

The company is pursuing two opportunities, the Diagnostics division is working on a rapid test for 2019-nCoV, which would quickly tell physicians if the case they are working on has the coronavirus. Since the CDC has made a test kit themselves and it has passed through FDA approval, I’m not sure what the purpose or status of the proposed test kit.

The other opportunity is a vaccine for the coronavirus using the company’s Ii-key peptide technology. I have interviewed lead scientist, Eric von Hofe, Ph.D., for another article. He told me that vaccines can be developed from their peptide technology, and that these can be developed relatively quickly, since it only a matter of producing amino acid peptide chains. Interestingly, another person on their team is James Anderson, M.D. who was at one time Chief of Medicine at the country’s biological warfare center, Ft. Detrick.

A PR announcement of 2/10/2020 quotes CEO Joseph Moscato: “We had a large and successful infectious disease program a decade ago when our subsidiary NuGenerex Immuno-Oncology (then Antigen Express) was developing Ii-Key hybrid vaccines against a range of pathogens including HIV, bird flu, swine flu, Ebola, and SARS, another coronavirus."  

Also, in PR Moscato says - “we have been working with Chinese entities and partners to deploy our Ii-Key peptide vaccine solution in China.” 

Technology agent: Ii-key peptide

Articles & PR’s:

Generex Biotechnology Subsidiaries NuGenerex Immuno-Oncology and NuGenerex Diagnostics Working to Address the Coronavirus Pandemic and Emerging Risk of Avian Flu Using Ii-Key Peptide Vaccines

Generex Biotechnology Subsidiaries NuGenerex Immuno-Oncology and NuGenerex Diagnostics Working to Address the Coronavirus Pandemic and Emerging Risk of Avian Flu Using Ii-Key Peptide Vaccines

Generex Biotechnology Discusses Coronavirus Solutions with The Stock Day Podcast

Moderna (MRNA)

Mentioned by Dr. Anthony Fauci from NIH, there is a lot of interest in Moderna’s approach, which has to be considered seriously after Fauci’s mention.

Technology agent: mRNA (messenger RNA)

Articles & PR’s:

3 Reasons To Buy Moderna

Moderna: Undervalued As The Promising Pipeline Awaits Collaborations

Investors rush into biotechs working on coronavirus vaccine

Moderna's stock jumps as health officials say virus vaccine development has 'no glitches'

Novavax (NVAX)

“Novavax has already developed vaccines targeting other types of coronavirus -- SARS and Middle East respiratory syndrome. However, neither vaccine has won regulatory approval.”

Technology agent: nanoparticle

Articles & PR’s:

Better Coronavirus Play: Johnson & Johnson vs. Novavax | The Motley Fool

Novavax: Be Careful With This One

Novavax: Investors Prepare For A Decisive 2020

Vir Biotechnology (VIR)

From "About" on their website: "We are taking a multi-program, multi-technology platform approach, assembled through internal development, collaborations, and acquisitions."

Technology agent: Platforms: antibody, T cell, innate, siRNA

Articles & PR’s:

Vir Biotechnology CEO on fighting the coronavirus outbreak

Vir Biotech 'Aggressively Working' On Potential Wuhan Coronavirus Treatment

Investors rush into biotechs working on coronavirus vaccine

Regeneron (REGN)

The company had developed something for Ebola a few years back, and expects to have treatments for 2019 nCoV in the next months.

Technology agent: monoclonal antibodies

Articles & PR’s:

Investors rush into biotechs working on coronavirus vaccine

Regeneron likely to make coronavirus treatments available in few months

Regeneron Shares Rise on Earnings, Coronavirus Work | The Motley Fool

Biocryst Pharmaceuticals (BCRX)

The company appears to have a candidate Galidesivir is in Phase I clinical study for several types of viruses including coronavirus

Technology agent:  Galidesivir

Articles and PR's

https://www.nasdaq.com/articles/why-biocryst-pharmaceuticals-stock-is-jumping-again-today-2020-01-27

Aethlon Medical (AEMD)

Aethlon has been working on coronaviruses for DARPA, especially the mideast coronavirus.

Technology agent:

Articles and PR's:

https://www.aethlonmedical.com/news-media/press-releases/detail/331/aethlon-medical-achieves-darpa-milestones-including-middle

= = = =

I own two of the above stocks. I did not buy either for its coronavirus technology, but that does mean they may not have valuable applicable technology.

I bought GNBT for its buccal tissue delivery of insulin (a spray that uses the blood rich buccal tissue inside the cheek to absorb insulin, not through lung absorption), its vaccine subsidiary (which is in a trial with Merck for triple negative breast cancer, but its Ii-key technology can be used against viruses), and now for its additional services and therapies it has acquired – wound treatment, a candidate for ulcerative colitis treatment, orthopedic tools and kits, an MSO (Medical Services Organization), in-office diagnostic kits, and most interestingly, a diabetes initiative in Arizona.

I bought CYDY for its candidate leronlimab, which appears to be useful against HIV, and in a recent test in two patients saw remarkable success against breast cancer.

It appears only one candidate is in progress, Gilead’s remdesivir. It appears only one company is working on a diagnostic test, Generex.  

I cannot speak to the science of any of these companies, except to say that unless a candidate is ready, it will take months to develop vaccine candidates, and they may or may not work. I don’t know which of the above companies will be successful in developing a useful 2019-nCoV coronavirus vaccine. I merely present information about companies engaged in working in the coronavirus area for interested investors.

I hope to update this page as time permits. I welcome interested parties to comment with their knowledge and insight, and additional information.

Original Article: 8Feb2020

Updated: 10Feb2020 [Opening remarks, Generex, Vir]

Updated: 12Feb2020 [Biocryst, Aethlon added]

Disclosure: I am/we are long GNBT CYDY.